Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Nov 4;64(5):688–693. doi: 10.1136/ard.2004.026658

A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs

V Rabenda 1, N Burlet 1, O Ethgen 1, F Raeman 1, J Belaiche 1, J Reginster 1
PMCID: PMC1755468  PMID: 15528282

Abstract

Objectives: To capture changes in the quality of life (QoL) occurring in patients with osteoarthritis (OA) during treatment with non-specific non-steroidal anti-inflammatory drugs (NSAIDs) and to identify factors that predict such changes.

Methods: A naturalistic, prospective follow up of 783 patients with OA in whom primary care physicians decided to start treatment with non-selective NSAIDs. Short Form-36 (SF-36) and the Western Ontario and McMaster Universities OA index (WOMAC) were assessed at baseline and after 3 months. Baseline results were compared with QoL values in 4800 subjects randomly selected from the general population. Multiple regression analysis was performed to identify determinants of QoL at baseline and measures influencing changes in SF-36 or WOMAC during follow up.

Results: All QoL dimensions were significantly (p<0.01) decreased in patients with OA compared with controls. Significant improvement (p<0.05) in four dimensions of the SF-36 (vitality, role emotional, role physical, bodily pain) and in all components of the WOMAC was seen between baseline and month 3. Older age, female sex, longer duration of OA, and a higher number of comorbidities were the major determinants of a poor QoL at baseline. Maximal benefit from non-specific NSAIDs was seen in patients with the most severe impairment in QoL and the shortest duration of OA.

Conclusion: OA negatively impacts all dimensions of the QoL. Non-specific NSAIDs improve the QoL in patients with OA treated in a "real life setting". The profile of patients receiving maximal benefit from such treatment may be of interest for health providers, enabling them to decide who should preferentially be given cytoprotective treatments or coxibs.

Full Text

The Full Text of this article is available as a PDF (92.3 KB).

Figure 1.

Figure 1

Open in a new tab

 Mean values of the various dimensions of the SF-36, by sex, in 783 subjects with OA and in a control cohort obtained from a random sample of 4800 Belgian citizens.

Figure 2.

Figure 2

Open in a new tab

 Mean values of the various dimensions of the SF-36 at baseline (>94% of the population) and at 3 months (>93% of the population) in a sample of 783 patients with OA.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellamy N., Buchanan W. W., Goldsmith C. H., Campbell J., Stitt L. W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):1833–1840. [PubMed] [Google Scholar]
  2. Bindman A. B., Keane D., Lurie N. Measuring health changes among severely ill patients. The floor phenomenon. Med Care. 1990 Dec;28(12):1142–1152. doi: 10.1097/00005650-199012000-00003. [DOI] [PubMed] [Google Scholar]
  3. Bradley J. D., Brandt K. D., Katz B. P., Kalasinski L. A., Ryan S. I. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991 Jul 11;325(2):87–91. doi: 10.1056/NEJM199107113250203. [DOI] [PubMed] [Google Scholar]
  4. Briggs A., Scott E., Steele K. Impact of osteoarthritis and analgesic treatment on quality of life of an elderly population. Ann Pharmacother. 1999 Nov;33(11):1154–1159. doi: 10.1345/aph.18411. [DOI] [PubMed] [Google Scholar]
  5. Bruyere Olivier, Honore Aline, Rovati Lucio C., Giacovelli Giampaolo, Henrotin Yves E., Seidel Laurence, Reginster Jean-Yves L. Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol. 2002;31(1):13–16. doi: 10.1080/030097402317255309. [DOI] [PubMed] [Google Scholar]
  6. Chambless L. E., Roeback J. R. Methods for assessing difference between groups in change when initial measurements is subject to intra-individual variation. Stat Med. 1993 Jul 15;12(13):1213–1237. doi: 10.1002/sim.4780121304. [DOI] [PubMed] [Google Scholar]
  7. Ethgen O., Tellier V., Sedrine W. B., De Maeseneer J., Gosset C., Reginster J-Y. Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision makers and payers? Bone. 2003 Jun;32(6):718–724. doi: 10.1016/s8756-3282(03)00089-9. [DOI] [PubMed] [Google Scholar]
  8. Hill C. L., Parsons J., Taylor A., Leach G. Health related quality of life in a population sample with arthritis. J Rheumatol. 1999 Sep;26(9):2029–2035. [PubMed] [Google Scholar]
  9. Hopman-Rock M., Kraaimaat F. W., Bijlsma J. W. Quality of life in elderly subjects with pain in the hip or knee. Qual Life Res. 1997 Jan;6(1):67–76. doi: 10.1023/a:1026421629416. [DOI] [PubMed] [Google Scholar]
  10. Jette Alan M., Haley Stephen M., Coster Wendy J., Kooyoomjian Jill T., Levenson Suzette, Heeren Tim, Ashba Jacqueline. Late life function and disability instrument: I. Development and evaluation of the disability component. J Gerontol A Biol Sci Med Sci. 2002 Apr;57(4):M209–M216. doi: 10.1093/gerona/57.4.m209. [DOI] [PubMed] [Google Scholar]
  11. La Montagna G., Tirri G., Cacace E., Perpignano G., Covelli M., Pipitone V., D'Agostino P., Magarò M., Ferraccioli G., Mascia M. T. Quality of life assessment during six months of NSAID treatment [Gonarthrosis and Quality of Life (GOAL) Study]. Clin Exp Rheumatol. 1998 Jan-Feb;16(1):49–54. [PubMed] [Google Scholar]
  12. Langman M., Kahler K. H., Kong S. X., Zhang Q., Finch E., Bentkover J. D., Stewart E. J. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):517–524. doi: 10.1002/pds.653. [DOI] [PubMed] [Google Scholar]
  13. Leplège A., Ecosse E., Verdier A., Perneger T. V. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol. 1998 Nov;51(11):1013–1023. doi: 10.1016/s0895-4356(98)00093-6. [DOI] [PubMed] [Google Scholar]
  14. Lin Jinying, Zhang Weiya, Jones Adrian, Doherty Michael. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004 Jul 30;329(7461):324–324. doi: 10.1136/bmj.38159.639028.7C. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McHorney C. A., Ware J. E., Jr, Lu J. F., Sherbourne C. D. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994 Jan;32(1):40–66. doi: 10.1097/00005650-199401000-00004. [DOI] [PubMed] [Google Scholar]
  16. McKenna F., Borenstein D., Wendt H., Wallemark C., Lefkowith J. B., Geis G. S. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol. 2001;30(1):11–18. doi: 10.1080/030097401750065265. [DOI] [PubMed] [Google Scholar]
  17. Pavelká Karel, Gatterová Jindriska, Olejarová Marta, Machacek Stanislav, Giacovelli Giampaolo, Rovati Lucio C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002 Oct 14;162(18):2113–2123. doi: 10.1001/archinte.162.18.2113. [DOI] [PubMed] [Google Scholar]
  18. Razavi D., Gandek B. Testing Dutch and French translations of the SF-36 Health Survey among Belgian angina patients. J Clin Epidemiol. 1998 Nov;51(11):975–981. doi: 10.1016/s0895-4356(98)00089-4. [DOI] [PubMed] [Google Scholar]
  19. Reginster J. Y. The prevalence and burden of arthritis. Rheumatology (Oxford) 2002 Apr;41(Suppl 1):3–6. [PubMed] [Google Scholar]
  20. Samsa G., Edelman D., Rothman M. L., Williams G. R., Lipscomb J., Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999 Feb;15(2):141–155. doi: 10.2165/00019053-199915020-00003. [DOI] [PubMed] [Google Scholar]
  21. Schnitzer Thomas J. Means, responders, and meaning: evaluation of clinical trials in osteoarthritis. Arthritis Rheum. 2003 Nov;48(11):3001–3003. doi: 10.1002/art.11329. [DOI] [PubMed] [Google Scholar]
  22. Sharma Leena, Cahue September, Song Jing, Hayes Karen, Pai Yi-Chung, Dunlop Dorothy. Physical functioning over three years in knee osteoarthritis: role of psychosocial, local mechanical, and neuromuscular factors. Arthritis Rheum. 2003 Dec;48(12):3359–3370. doi: 10.1002/art.11420. [DOI] [PubMed] [Google Scholar]
  23. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]
  24. Wiklund I. Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. Can J Gastroenterol. 1999 Mar;13(2):129–133. doi: 10.1155/1999/171408. [DOI] [PubMed] [Google Scholar]
  25. Yeomans N., Wilson I., Långström G., Hawkey C., Naesdal J., Walan A., Wiklund I. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol. 2001;30(6):328–334. doi: 10.1080/030097401317148516. [DOI] [PubMed] [Google Scholar]
  26. Yocum D., Fleischmann R., Dalgin P., Caldwell J., Hall D., Roszko P. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000 Oct 23;160(19):2947–2954. doi: 10.1001/archinte.160.19.2947. [DOI] [PubMed] [Google Scholar]
  27. Zhao S. Z., Dedhiya S. D., Bocanegra T. S., Fort J. G., Kuss M. E., Rush S. M. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee. Clin Ther. 1999 Jan;21(1):205–217. doi: 10.1016/S0149-2918(00)88279-X. [DOI] [PubMed] [Google Scholar]
  28. de Bock G. H., Kaptein A. A., Touw-Otten F., Mulder J. D. Health-related quality of life in patients with osteoarthritis in a family practice setting. Arthritis Care Res. 1995 Jun;8(2):88–93. doi: 10.1002/art.1790080206. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES